This review explores the impact of menopause on metabolic dysfunction and the role of menopausal hormone therapy (MHT) in mitigating components of metabolic syndrome (MetS), including visceral obesity, dyslipidemia, type 2 diabetes (T2D), and hypertension (HTN). MHT has been shown to improve body composition, lipid profiles, insulin sensitivity, and blood
